EPO Upholds Teva’s Copaxone 40mg Dosing-Regimen Patent
Teva has won a victory in persuading the European Patent Office to uphold a Copaxone dosing patent that it had granted. But national courts may take a different view on validity.
You may also be interested in...
Mylan has celebrated a reversal from the European Patent Office that has seen a key patent protecting Teva’s higher-strength 40mg/ml thrice-weekly version of Copaxone deemed invalid and revoked across Europe. Meanwhile, Teva has commented on the possibility of an appeal.
Teva has been refused by Ireland’s High Court an injunction to stop Mylan producing its US rival to Copaxone (glatiramer acetate) 40mg/ml at a local facility in Inverin, County Galway. The Israeli firm had claimed that Mylan’s production of the generic version of the multiple-sclerosis brand infringed the Irish counterpart of European patent EP2,949,335, titled ‘low frequency glatiramer acetate therapy’.
Mylan has launched partner Synthon’s Brabio (glatiramer acetate) 40mg/ml in the UK, the first generic of Teva’s thrice-weekly Copaxone formulation to treat relapsing forms of multiple sclerosis available to the UK’s National Health Service (NHS).